US FDA advisory panel narrowly votes to expand use of Eli Lilly's Cymbalta for pain
In a decision that was not widely expected given ongoing liver damage concerns, a US Food and Drug Administration advisory panel yesterday voted by a narrow eight to six to back expanded use of drug major Eli Lilly's (NYSE: LLY) antidepressant Cymbalta (duloxetine).
Notwithstanding, Lilly ' which is facing patent expiry on several of its top-selling drugs (including Cymbalta in 2013) ' saw its share price dip a further 1.5% to $34.25 in late afternoon trading. Also, there was a bit of good news for the company, which yesterday also heard that Judge Dennis Cavanaugh of District Court in Newark ordered that no generic version of the Lilly attention-deficit hyperactivity disorder (ADHA) drug Strattera (atomoxetine) be allowed on the market after the firm brought to the market for at least two weeks, after the company filed for action to give it time to appeal a negative court ruling on the drug's patent (The Pharma Letters August 16 and 18),.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze